Clinical TrialPMNNCT07425691

SPACE for Youth With Chronic Pain FDA Decision: ProMIS Neurosciences (PMN)

Decision Date
June 30, 2026
26 days away

Drug Overview

Drug / TherapySPACE for Youth With Chronic Pain
Indication—
Decision TypeClinical Trial
Trial PhaseClinical Trial
ClinicalTrials.govNCT07425691

Company Overview

ProMIS Neurosciences (PMN) operates in the Misfolded Protein ALS/AD sector. The current BTS Score is 42 (Grade: D).

Dilution Risk Assessment

Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.

Frequently Asked Questions

Q:When is the Clinical Trial date for SPACE for Youth With Chronic Pain?

The Clinical Trial date for SPACE for Youth With Chronic Pain by ProMIS Neurosciences (PMN) is scheduled for June 30, 2026. This is the target date for the FDA to make a decision on this application.

Q:What is SPACE for Youth With Chronic Pain used for?

SPACE for Youth With Chronic Pain is being developed by ProMIS Neurosciences for the treatment of its target indication. It is currently in Clinical Trial clinical trials.

Q:What happens if SPACE for Youth With Chronic Pain gets FDA approval?

If SPACE for Youth With Chronic Pain receives FDA approval, ProMIS Neurosciences (PMN) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Clinical Trial date closely.

Q:What is the dilution risk for PMN?

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for PMN on DilutionWatch at dilutionwatch.com/stock/PMN.html.

Q:Where can I find more information about ProMIS Neurosciences?

You can view the full BiotechSigns company profile for ProMIS Neurosciences (PMN) at biotechsign.com/app/company/PMN, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.

Disclaimer

This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.